News and Press Releases
Epsilogen and Lonza Announce Successful Large-Scale GMP Manufacturing of MOv18, an IgE Antibody Targeting Ovarian Cancer
First time GMP manufacturing of a therapeutic IgE antibody has been achieved at scale GMP material to be used in phase 1b study in platinum-resistant ovarian cancer (PROC) patients scheduled...
Category: BioManufacturing
Posted: March 5, 2024
Ellipses’ next generation selective RET inhibitor EP0031/A400 granted Fast Track designation by US Food and Drug Administration
Compound is currently undergoing clinical trials as a potential treatment option for patients with RET altered tumours 5 March 2024 -- London, UK -- Ellipses Pharma, a global drug development...
Category: Drug Discovery
Posted: March 5, 2024
Exonate first-in-class eye drop phase 1b/2a trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema
EXN407 is the first topical SRPK1 inhibitor to demonstrate both safety and signals of biological response as monotherapy for these indications Data generated fully supports continued clinical development of EXN407...
Category: Clinical Trials
Posted: March 5, 2024
New Data Demonstrate Sunbird Bio’s APEX Diagnostic Test Accurately Differentiates Key Alzheimer’s Disease Biomarker in Blood
Blood-based diagnostic effectively discriminated between patients who were positive versus negative for amyloid beta on PET scans Data will be shared in a poster presentation at AD/PD 2024 on 8-9...
Category: Biotechnology
Posted: March 5, 2024
Jemperli (dostarlimab) becomes the first immunotherapy treatment to receive NICE recommendation for use, in line with its license, in eligible endometrial cancer patients in first line setting
This final draft guidance recommends the use of dostarlimab in combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or...
Category: Clinical Trials, Drug Discovery
Posted: March 5, 2024
Audion Therapeutics and the REGAIN Consortium Announce Publication in Nature Communications of Their Phase 1/2a Trial of an Intratympanic Gamma Secretase Inhibitor for the Treatment of Mild to Moderate Sensorineural Hearing Loss
The phase 1 part of the study (Multiple Ascending Dose of 3 administrations) confirms safety and tolerability of a dose of 250 microgram of Gamma Secretase Inhibitor LY3056480 Pre-defined Primary...
Category: Clinical Trials
Posted: March 4, 2024
Linnaeusparkweg 10-2, 1098 EA Amsterdam, Netherlands
CatSci Ltd Win Welsh Government SMART Capital Equipment Grant for Innovative Oligonucleotides Development to Address Previously Unmet Needs
4 March 2024 -- Cardiff, Wales -- CatSci, an award-winning innovation partner for medicines development, are thrilled to announce that they have won a Welsh Government SMART Capital Equipment Fund...
Category: Biotechnology
Posted: March 4, 2024
SolasCure Publishes Phase 2a Clinical Trial Report in Leading Wound Care Journal
Publication in the ‘International Wound Journal’ provides robust validation of the phase 2a trial data that will enable further clinical studies Study demonstrates proof-of-concept and strong safety profile of Aurase...
Category: Biotechnology
Posted: March 4, 2024
WCG Expands New Statistical Consulting Solutions to Address Industry Resource Challenges
4 March 2024 -- New Jersey, US -- WCG, the global leader in providing solutions that measurably improve and accelerate clinical research, announces the expansion of its capabilities with the...
Category: Clinical Trials
Posted: March 4, 2024
PharmaKure announces epigenetics collaboration with Sheffield Hallam University to understand mechanisms of Alzheimer’s Diseases
New collaboration will enhance ability to identify those more at risk of developing brain diseases to enable earlier interventions 29 February 2024 -- Manchester, UK -- PharmaKure, a clinical stage...
Category: Other
Posted: February 29, 2024
Alderley Park Congleton Road Nether Alderley Open Access Lab 19S6 Macclesfield SK10 4TG
SPT Labtech and RevoluGen demonstrate fully automated bead-based high molecular weight DNA extraction
The collaboration delivers a walk-away solution suitable for high-throughput long-read sequencing in under two hours 28 February 2024 – Cambridge, UK – SPT Labtech, a global leader in the design,...
Category: BioManufacturing, Biotechnology, Drug Discovery
Posted: February 29, 2024
SPT Labtech Ltd. Melbourn Science Park Melbourn Hertfordshire SG8 6HB United Kingdom
Clinigen launches ‘What is Possible?’ campaign to accelerate access to medicines on Rare Disease Day
With over 7,000 rare diseases that impact over 300 million people globally, just 5% of rare diseases have a licensed treatment 29 February 2024 -- London, UK -- Clinigen, the...
Category: Other
Posted: February 29, 2024
Rare Disease Day: Emmes Endpoints Solutions submits Duchenne Video Assessment Qualification plan to FDA
26 February 2024 – Plymouth, MA, US – Emmes Endpoints Solutions* has submitted its Duchenne Video Assessment (DVA) qualification plan to the U.S. Food and Drug Administration (FDA) Center for...
Category: Drug Discovery
Posted: February 28, 2024
Why rare disease day is so important – Julie Matthews, CEO at TMC Pharma
Because each individual rare or orphan disease has such a low public profile, advocacy for research funding depends on a collective effort through channels such as Rare Disease Day. Whilst...
Category: Drug Discovery
Posted: February 28, 2024
Lodge Farm Barn Elvetham Park Estate, Fleet Road, Hartley Wintney, Hampshire RG27 8AS, UK
Galimedix Therapeutics announces new pre-clinical data with GAL-201 in an Alzheimer’s disease transgenic model to be presented at AD/PD 2024 Conference
Galimedix’s novel, orally administered small molecule offers the hope of changing the course of disease by targeting amyloid beta oligomers and protofibrils 28 February 2024 -- Maryland, US -- Galimedix...
Category: Biotechnology
Posted: February 28, 2024
